ADCendo - Bamdej Communication
Duality Biologics-Duality Biologics
Adcendo raises $61M series A round to advance uPARAP-targeting ADC candidate | BioWorld
ADCendo ApS raises €51m in Series A financing - European Biotechnology
BioCentury - May 30 Quick Takes: China deals for C4, Adcendo
Leadership team | Adcendo
Carl Kilander on LinkedIn: Adcendo ApS Announces Option License Agreement with Duality Biologics to…
Press releases | Adcendo
Adcendo
ADCendo - Org Chart, Teams, Culture & Jobs | The Org
BioCentury - ADCendo: entering tumors via MRC2
Gilde Healthcare company Adcendo Aps Announces License Agreement with Duality Biologics on Next-generation ADC Platform - Gilde Healthcare
Duality Biologics Announces License Agreement of its Next-generation ADC platform with Adcendo
GlyTherix and Adcendo Announce Agreement for Development of Antibody Drug Conjugate - GlyTherix
Adcendo
Adcendo ApS Announces License Agreement with Duality Biologics on Next-generation ADC Platform
映恩生物与Adcendo公司就ADC平台技术达成合作-药选址
Adcendo ApS Announces Option License Agreement with Duality Biologics – Ysios Capital
Adcendo Benefits From ADC Excitement To Raise More Cash :: Scrip
Adcendo | LinkedIn
Adcendo Appoints Dr. Lone H. Ottesen as CMO – Ysios Capital
Adcendo, Duality Biologics To Further Expand First-in-Class ADC Pipeline | Contract Pharma
ADCendo - Bamdej Communication
The uPARAP receptor | Adcendo
